Implementation of a new guideline in cardiovascular secondary preventive care: subanalysis of a randomized controlled trial

Table 2 Lipid lowering treatments after the guideline change

	Before medication titration			After medication titration
	Intervention	Control	P-value	Intervention	Control	P-value
No treatment (%)	12.9	11.0	0.68	4.0	9.0	0.15
Simvastatin (%)	33.7	52.0	0.009	21.8	51.0	<0.001
Simvastatin 10 mg	2.0	5.0	0.24	1.0	6.0	0.05
Simvastatin 20 mg	14.9	25.0	0.07	9.9	21.0	0.03
Simvastatin 40 mg	16.8	22.0	0.35	10.9	24.0	0.01
Atorvastatin (%)	44.6	35.0	0.17	56.4	38.0	0.009
Atorvastatin 20 mg	6.9	13.0	0.15	5.0	14.0	0.03
Atorvastatin 40 mg	25.7	19.0	0.25	29.7	21.0	0.16
Atorvastatin 60 mg	0	1.0	0.31	0	1.0	0.31
Atorvastatin 80 mg	11.9	2.0	0.006	22.8	2.0	<0.001
Rosuvastatin (%)	4.0	0	0.04	8.9	0	0.002
Rosuvastatin 20 mg	3.0	0	0.08	3.0	0	0.08
Rosuvastatin 40 mg	1.0	0	0.32	5.9	0	0.01
Other^a (%)	5.0	2.0	0.25	7.9	2.0	0.05

^aPravastatin 40 mg, combination of atorvastatin 80 mg and ezetimib 10 mg or combination of rosuvastatin 40 mg and ezetimib 10 mg

ISSN: 1471-2261